Ligand Pharma (LGND) Stock Forecast & Price Target

Compare

819 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LGND Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Ligand

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LGND Stock 12 Month Forecast

Average Price Target

$164.80

▲(4.76% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Ligand Pharma in the last 3 months. The average price target is $164.80 with a high forecast of $185.00 and a low forecast of $155.00. The average price target represents a 4.76% change from the last price of $157.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"100":"$100","143":"$143","186":"$186","121.5":"$121.5","164.5":"$164.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":164.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$164.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[100,121.5,143,164.5,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.72,136.74153846153845,140.7630769230769,144.7846153846154,148.80615384615385,152.8276923076923,156.84923076923076,160.8707692307692,164.8923076923077,168.91384615384615,172.9353846153846,176.9569230769231,180.97846153846154,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.72,135.18769230769232,137.6553846153846,140.12307692307692,142.59076923076924,145.05846153846153,147.52615384615385,149.99384615384616,152.46153846153845,154.92923076923077,157.3969230769231,159.86461538461538,162.3323076923077,{"y":164.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.72,134.43384615384616,136.1476923076923,137.86153846153846,139.57538461538462,141.28923076923076,143.00307692307692,144.71692307692308,146.43076923076924,148.14461538461538,149.85846153846154,151.5723076923077,153.28615384615384,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$185.00

Average Price Target$164.80

Lowest Price Target$155.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

08/12/25

Ligand Pharma (LGND) Gets a Buy from Craig-Hallum

Douglas Miehm

RBC Capital

$155→$185

Buy

17.60%

Upside

Reiterated

08/10/25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Establishment Labs Holdings (NASDAQ: ESTA) and GH Research (NASDAQ: GHRS)

Robert Wasserman

Benchmark Co.

$135→$160

Buy

1.71%

Upside

Reiterated

08/08/25

Ligand price target raised to $160 from $135 at BenchmarkLigand price target raised to $160 from $135 at Benchmark

Annabel Samimy

Stifel Nicolaus

$143→$155

Buy

-1.47%

Downside

Reiterated

08/08/25

Analysts Are Bullish on Top Healthcare Stocks: Insmed (INSM), Ligand Pharma (LGND)

Joseph Pantginis

H.C. Wainwright

$157

Buy

-0.20%

Downside

Reiterated

08/08/25

Positive Outlook on Ligand Pharma: Strong Financial Performance and Strategic Positioning Drive Buy Rating

Trevor Allred

Oppenheimer

$162→$167

Buy

6.16%

Upside

Reiterated

08/07/25

Oppenheimer Remains a Buy on Ligand Pharma (LGND)

Balaji Prasad

Barclays

$160

Buy

1.71%

Upside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

08/12/25

Ligand Pharma (LGND) Gets a Buy from Craig-Hallum

Douglas Miehm

RBC Capital

$155→$185

Buy

17.60%

Upside

Reiterated

08/10/25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Establishment Labs Holdings (NASDAQ: ESTA) and GH Research (NASDAQ: GHRS)

Robert Wasserman

Benchmark Co.

$135→$160

Buy

1.71%

Upside

Reiterated

08/08/25

Ligand price target raised to $160 from $135 at BenchmarkLigand price target raised to $160 from $135 at Benchmark

Annabel Samimy

Stifel Nicolaus

$143→$155

Buy

-1.47%

Downside

Reiterated

08/08/25

Analysts Are Bullish on Top Healthcare Stocks: Insmed (INSM), Ligand Pharma (LGND)

Joseph Pantginis

H.C. Wainwright

$157

Buy

-0.20%

Downside

Reiterated

08/08/25

Positive Outlook on Ligand Pharma: Strong Financial Performance and Strategic Positioning Drive Buy Rating

Trevor Allred

Oppenheimer

$162→$167

Buy

6.16%

Upside

Reiterated

08/07/25

Oppenheimer Remains a Buy on Ligand Pharma (LGND)

Balaji Prasad

Barclays

$160

Buy

1.71%

Upside

Reiterated

03/10/25

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ligand Pharma

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+1.53%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +1.53% per trade.

3 Months

xxx

Success Rate

23/35 ratings generated profit

Average Return

+9.03%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +9.03% per trade.

1 Year

Robert WassermanBenchmark Co.

Success Rate

13/15 ratings generated profit

Average Return

+33.37%

reiterated a buy rating 16 days ago

Copying Robert Wasserman's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +33.37% per trade.

2 Years

xxx

Success Rate

13/15 ratings generated profit

Average Return

+47.13%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +47.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LGND Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LGND has received 12 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. LGND average Analyst price target in the past 3 months is 164.80.

Each month's total comprises the sum of three months' worth of ratings.

LGND Financial Forecast

LGND Earnings Forecast

Next quarter’s earnings estimate for LGND is $1.90 with a range of $1.60 to $2.09. The previous quarter’s EPS was $1.60. LGND beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year LGND has Outperformed its overall industry.

LGND Sales Forecast

Next quarter’s sales forecast for LGND is $58.64M with a range of $50.15M to $63.70M. The previous quarter’s sales results were $47.63M. LGND beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year LGND has Outperformed its overall industry.

LGND Stock Forecast FAQ

What is LGND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ligand Pharma’s 12-month average price target is 164.80.

What is LGND’s upside potential, based on the analysts’ average price target?

Ligand Pharma has 4.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LGND a Buy, Sell or Hold?

Ligand Pharma has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ligand Pharma’s price target?

The average price target for Ligand Pharma is 164.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $155.00. The average price target represents 4.76% Increase from the current price of $157.31.

What do analysts say about Ligand Pharma?

Ligand Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of LGND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ligand Pharma (LGND) Stock Forecast & Price Target

LGND Analyst Ratings

LGND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ligand Pharma

LGND Analyst Recommendation Trends

LGND Financial Forecast

LGND Earnings Forecast

LGND Sales Forecast

LGND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts